No one expected that the famous venture capital boss in Silicon Valley would suddenly withdraw from the Internet industry, and it was so completely that he directly transferred all his investment industries in the entire Internet industry to his "little brother" - Pioneer Fund.

However, what everyone didn't expect was that the Ginkgo Fund, which had just withdrawn from Silicon Valley and the Internet industry not long ago, did not stop for a moment to make such a big event.

The $3.5 billion acquisition of a 70% stake in Amgen, a rising star in the biopharmaceutical industry, really gave everyone a big exclamation point. Yes, this news is so amazing, both Wall Street and the venture capital community are a little confused about what the Ginkgo Fund wants to do?

Indeed, the flickering and moving of the Ginkgo Fund really made many people directly confused, and they couldn't understand this wave of divine operation at all!

Nima, what the hell is this? Is it a trick to die?

Abandon the hot Internet industry and invest in the biomedical industry - is this Shi Lezhi?

Yes, the "money scene" of the biomedical industry is very bright, but the wave of the current era is obviously in the Internet industry.

Besides, no matter how high and fast the rate of return on capital in the Internet industry is, investing in a company will not take a few years to go public and make money, and you can make a lot of money. Of course, there must be people who lose money, but the absolute force of losing money is only a small part, and their investment is fast, accurate, and ruthless.

Compared with the Internet industry, the biomedical industry is a bit of a pain, very simple, because although this thing makes money, and it is very profitable, the money-making cycle is still very long and long-lasting - a biomedical technology or a drug can make money for more than ten years or even decades. However, there is one thing that is quite embarrassing for investors, that is, the investment cost of this thing is too large and the cycle is too long. Moreover, unlike the Internet industry, where you can fool people to make money by relying on an idea, who would be so stupid to be deceived if you don't come up with something real in the biomedical industry.

Therefore, after the announcement of Ginkgo Fund's acquisition of Amgen, a rising star in biomedicine, many people were quite incomprehensible.

I have to say that this is really a group of "mortals", but yes, how would they know that Amgen will be like that in the future - a $130 billion biomedical giant, which is not at all worse than those century-old pharmaceutical giants, or even stronger.

"Mortals" are mortals, how could they know about the "divine operation" of Su Chenyu and the Ginkgo Fund, and next, there are even more incomprehensible manipulations of "mortals".

After buying a 70% stake in Amgen for $3.5 billion, Ginkgo once again chose to make a move, formalizing an agreement with Goldman Sachs and Lehman Brothers to acquire a total of 8% of Amgen's shares.

As a result, Ginkgo Fund has shown quite aggressive intentions, and controlling 78% of the shares is no longer just a strategic investment. Obviously, Ginkgo Fund is very optimistic about Amgen's future and has decided to take it directly.

In fact, it is true, according to the development trajectory of Amgen, the profits will gradually soar every year in the future, and Su Chenyu has no reason not to directly take it for himself. It is no exaggeration to say that the valuation of 5 billion yuan of Ginkgo Fund seems to be a lot, but according to the normal development of Amgen, this investment can easily be earned in a few years.

So, naturally, Ginkgo applied to the SEC to privatize Amgen, and it was no surprise that the SEC quickly agreed to Amgen's privatization process — and besides, Amgen is not an industry giant, nor does it involve any monopoly or monopoly.

For the sudden privatization of Ginkgo Fund, many people are dumbfounded again, there is no way, this should not be what a venture capital should do. After all, fast in and fast out is what venture capital does, how can there be any such industry management.

Hehe, these ignorant humans.

No one expected that the privatization of Amgen by Ginkgo Fund here has not ended, and a big nuclear bomb has exploded over there - Genentech, the longest-established biotechnology company in the United States, has been controlled by Ginkgo Fund.

I'm a big nuclear bomb!

Another biotechnology company was swallowed up by Ginkgo Fund, which shows that Ginkgo Fund's entry into the biomedical industry is really not just a joke, but a real play.

Genentech, although not as large as Amgen, should be regarded as a giant in the biotechnology industry. Therefore, Ginkgo Fund's merger and acquisition of Genentech is definitely a more violent signal - the SS consortium is likely to have targeted the big industry of biomedicine, and even more attentive than the Internet industry.

After all, who doesn't know that Ginkgo Fund is another "capital minion" of the SS consortium, and even their style is more SS consortium than Tianchen Fund in some things - that is, more fierce and ferocious. Over the years, because of its increasing size and influence, Tianchen Fund has gradually become much gentler in its style, and has lost the ruthlessness and ferocity that the SS consortium has always been.

However, looking at what Ginkgo Fund has done in Silicon Valley for such a long time, it is absolutely ruthless and ferocious, as long as it is the target they see, they will definitely win it by any means - no matter who the opponent is. Even a veteran Silicon Valley venture capital boss like Sequoia Fund has been by Ginkgo Fund several times, and he has been made to say that he can't say it.

Therefore, now that the SS consortium has let this "pioneer" Ginkgo fund enter the biomedical industry on such a large scale, it must be extremely optimistic about this industry. After all, the SS consortium seems to have never missed its strategic vision for so many years.

Next, Ginkgo Fund's actions once again made many people think more, because just after Amgen was successfully privatized, the privatization of Genentech was officially put on the agenda.

After successfully taking a 60% stake in Genentech from Roche Pharmaceuticals for $2.5 billion, Ginkgo Fund made another move to acquire a 26% stake in Genentech for $1.1 billion — bringing the total number of Genentech shares controlled by Ginkgo Fund to 86%.

Later, Ginkgo Fund officially launched the privatization process of Genentech, and the "small" company with a market value of less than $4 billion soon became a wholly owned subsidiary of Ginkgo Fund.

After taking control of Amgen and Genentech, Ginkgo Fund officially announced that it would restructure the two biotech companies - as for Amgen and Genentech, who is the master and who is the second, there will be results soon.

Genentech's main research and business areas are endocrinology, metabolic diseases, cardiology, and gene therapy, while Amgen has strong capabilities in cardiovascular, diabetes, cardiovascular disease, and cancer. As a result, there is no business conflict between Amgen and Genentech, and to a large extent, their businesses complement each other quite perfectly. The most important thing is that once the R&D capabilities of the two companies are combined, they will make great strides in the research and development of cancer and HIV.

Soon, Ginkgo Fund's restructuring plan for Genentech and Amgen was officially released, and Amgen wholly owned Genentech. After the reorganization, Amgen and Genentech will merge and reorganize in terms of R&D capabilities and research data, but the management and operation of the two companies will be operated independently and each will retain its own brand.

This restructuring plan did not surprise many people, after all, Amgen is indeed more powerful than Genentech in some aspects. Besides, whether it's Amgen or Genentech, what difference does it make who is in charge? After all, both of them are wholly-owned subsidiaries of Ginkgo Fund.

After the completion of the restructuring of Amgen and Genentech, it will suddenly become the world's largest biotechnology company, and they will form a huge suppression of the entire industry in some key technologies. However, fortunately, the size of the two companies is still small, and if these two companies were tens of billions of giants before, the US Antitrust Commission would have been unable to sit still.

But even so, if Amgen and Genentech grow up in the same way as their predecessors, they will essentially dominate the global biotech industry. The most important thing is that if Amgen and Genentech are re-listed later, the market value of $100 billion will be unstoppable - that's the point.

However, since Su Chenyu is so optimistic about the biomedical industry, he will naturally not just make more than 100 billion US dollars, it is just a one-shot deal, besides, this money can't run, so just leave it there.

Again, since it has been decided, it is natural to be the biggest and strongest, and what Su Chenyu wants is not just a biomedical company, but a biomedical giant, and even an industry overlord!

Even, what Su Chenyu wants more is the entire biomedical era in the future, so Amgen and Genentech are just the beginning......